Picture of Nurix Therapeutics logo

NRIX — Nurix Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapSuper Stock

Nurix Therapeutics Inc reports results for the quarter ended in May - Earnings Summary

* Nurix Therapeutics Inc  NRIX.OQ  reported a quarterly
adjusted
loss of 71 cents​​ per share for the quarter ended in May, lower
than the same quarter last year, when the company reported EPS
of -45 cents.  The mean expectation of twelve analysts for the
quarter was for a loss of 63 cents per share. Wall Street
expected results to range from -85 cents to -40 cents per share.
    * Revenue fell 60.6% to $12.09 million from a year ago;
analysts
expected $22.11 million. 
    * Nurix Therapeutics Inc's reported EPS for the quarter was
a loss
of 71 cents​.
    * The company reported a quarterly loss of $44.55 million.
    * Nurix Therapeutics Inc shares had fallen by 3.0% this
quarter and gained 96.1% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 17.1%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Nurix
Therapeutics Inc is $26.00 
This summary was machine generated from LSEG data July 11 at
09:01 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 May. 31 2024      -0.63          -0.71          Missed
 Feb. 29 2024      -0.80          -0.76          Beat
 Nov. 30 2023      -0.57          -0.77          Missed
 Aug. 31 2023      -0.76          -0.68          Beat

Recent news on Nurix Therapeutics

See all news